ArticleBlood2023
How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy.
Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Guideline
- Donor lymphocyte infusion as immune modulation after pediatric allogeneic transplantation.Blood immunology & cellular therapy · 2026Article
- Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysis.Annals of hematology · 2026Article
- BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ.MedComm · 2026Article
- Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report.Frontiers in immunology · 2026Article
- Engineered natural killer cells for cancer therapy.Cancer cell · 2025Review
- Article
- TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation.Cancer science · 2025Article
- Article
- Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.European journal of haematology · 2025Article
- Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.Frontiers in immunology · 2025Review
- Biosurfactant Nanomicelles and Peptide Integration: Novel Approaches to Targeted Gene Delivery in Colon Cancer Treatment.Current medicinal chemistry · 2025Review
- Maintenance strategies for relapse prevention and treatment.Hematology. American Society of Hematology. Education Program · 2024Review
- Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (Blood science (Baltimore, Md.) · 2024Article
- CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.Nature communications · 2024Article
- Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation.Cells · 2024Review
- Transplant Eligible and Ineligible Elderly Patients with AML-A Genomic Approach and Next Generation Questions.Biomedicines · 2024Review
- Article
- Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes.Frontiers in immunology · 2024Review
- Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.Frontiers in immunology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for patients with high-risk acute leukemias, but unfortunately disease recurrence remains the major cause of death in these patients. Infusion of donor lymphocytes (DLI) has the potential to restore graft-versus-leukemia immunologic surveillance; however, efficacy varies across different hematologic entities. Although relapsed chronic myeloid leukemia, transplanted in chronic phase, has proven remarkably susceptible to DLI, response rates are more modest for relapsed acute myeloid leukemia and acute lymphoblastic leukemia. To prevent impending relapse, a number of groups have explored administering DLI preemptively on detection of measurable residual disease (MRD) or mixed chimerism. Evidence for the effectiveness of this strategy, although encouraging, comes from only a few, mostly single-center retrospective, nonrandomized studies. This article seeks to (1) discuss the available evidence supporting this approach while highlighting some of the inherent challenges of MRD-triggered treatment decisions post-transplant, (2) portray other forms of postremission cellular therapies, including the role of next-generation target-specific immunotherapies, and (3) provide a practical framework to support clinicians in their decision-making process when considering preemptive cellular therapy for this difficult-to-treat patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.